79280-92-5Relevant academic research and scientific papers
TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS
-
Page/Page column 142, (2021/04/23)
Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.
PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE
-
Paragraph 0395-0396, (2021/09/26)
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen
COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES
-
Paragraph 00275-00276, (2019/03/12)
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
HETEROCYCLIC COMPOUND
-
Paragraph 0742; 0743, (2017/10/17)
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF
-
Paragraph 0341; 0342, (2015/07/27)
Multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring of a substituted biphenyl core and having an h
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Paragraph 0153, (2016/01/29)
no abstract published
Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors
Liao, Weike,Xu, Chen,Ji, Xiaohui,Hu, Gang,Ren, Lixiang,Liu, Yajing,Li, Ruijuan,Gong, Ping,Sun, Tiemin
, p. 508 - 518 (2015/01/09)
A series of 4-(2-fluorophenoxy)quinoline derivatives containing an acylhydrazone moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and five cancer cell lines (A549, H460, HT-29, MKN-45, and U87MG). Most compounds showed weak to excellent antiproliferative activity. The most promising analog, 40 (c-Met IC50 Combining double low line 1.86 nM), displayed 1.3-, 6.8-, 1.5-, 3.5-fold increase against HT-29, H460, A549 and U87MG cell lines, respectively, compared with Foretinib. An analysis of structure-activity relationships revealed that an acylhydrazone scaffold with an unsubstituted sp2 hybridized carbon adjacent to the 4-CF3 phenyl ring is favorable for antitumor activity.
MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF
-
Page/Page column 67; 68, (2014/03/21)
The invention provides novel multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring of a substituted
MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF
-
Page/Page column 79, (2014/03/21)
The invention provides novel multitarget inhibitors of the enzymes Fatty Acid Amide Hydrolase (FAAH), Cyclooxygenase-1 (COX-1) and/or Cyclooxygenase-2 (COX-2) having a specific carbamate moiety on the meta or ortho position of the A ring of a substituted
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
Page/Page column 37, (2013/05/21)
The present invention provides compounds of Formula I I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
